上海艾力斯医药科技股份有限公司2025年年度业绩预增公告

Group 1 - The company expects to achieve an operating income of 5.2 billion yuan in 2025, an increase of 1.642 billion yuan or 46.15% compared to the previous year [2] - The projected net profit attributable to the parent company for 2025 is 2.15 billion yuan, reflecting an increase of 720 million yuan or 50.37% year-on-year [2] - The net profit attributable to the parent company after deducting non-recurring gains and losses is expected to be 2 billion yuan, up by 639 million yuan or 46.95% compared to the previous year [2] Group 2 - In 2024, the company achieved an operating income of 3.55793 billion yuan and a net profit of 1.4298471 billion yuan [2] - The basic earnings per share for 2024 were 3.18 yuan [2] - The company focuses on precision treatment for lung cancer, gaining recognition for its differentiated clinical treatment advantages and specialized academic promotion strategies [3] Group 3 - The company's core product sales revenue continues to grow, supported by national medical insurance policies that make new and effective drugs more accessible [3] - The company has optimized resource allocation and leveraged synergies among commercialized products to drive sustained operational performance [3]